{"a":[{"_":"Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancer","$":{"href":"/biotech/cullinan-taiho-prove-6-month-survival-benefit-phase-3-trial-advanced-lung-cancer","hreflang":"en"}}]}
Phase 3positiveRybrevantPositive
AI Analysis
Summary
Cullinan Therapeutics and Taiho Oncology reported phase 3 data demonstrating survival improvements superior to Johnson & Johnson's Rybrevant in patients with advanced non-small cell lung cancer in the front-line setting.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Survival improvements greater than Johnson & Johnson's Rybrevant in advanced non-small cell lung cancer front-line setting
Importance:8/10
Sentiment:
0.85
oncologylung cancerphase 3survival benefitclinical trial
Read the original article
Published by FierceBiotech on September 11, 2026 2:08 PM